Inve India ▾
ACACCENTMIC

Accent Microcell Q1 FY26 results (Apr–Jun 2025) and concall

Healthcare · Concall AI · Call held 7 Aug 2025

Accent Microcell's Q1 FY26 earnings call focused heavily on future growth and capacity expansion rather than current quarter financials. The company projects a 15-20% CAGR over the next 3-5 years and an improved weighted average EBITDA margin of 20-22% with the commissioning of Unit 3 Phase 1 (Oct/Nov 2025) and Phase 2 (July 2026). A new multinational customer for microsterized cellulose was announced, signaling strong future demand. Concerns include low profitability in the domestic market and increased debtor days.

You’re reading a preview. Opening the full call uses 1 concall credit.

Sign in to use your monthly call allowance.

What they filed before this quarter

₹ Cr · quarterly
Line itemQ2 FY24Q4 FY24Q2 FY25Q4 FY25
Revenue107 139 126 139
EBITDA20 20 19 23
Net profit14 16 16 17
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.